<DOC>
	<DOCNO>NCT01955421</DOCNO>
	<brief_summary>This study multicenter , randomize , open-label Phase II trial compare reduce dose erlotinib 100mg daily standard dose gefitinib 250mg daily patient advance non-small cell lung cancer harbor EGFR mutation . The primary endpoint disease control rate ( DCR ) key secondary endpoint progression free survival ( PFS ) . A total 224 eligible patient randomize receive either erlotinib 100mg daily gefitinib 250mg daily 1:1 ratio patient experience disease progression . Independent assessment major endpoint complete treatment-blinded manner . Randomization stratify base treatment-lines ( first-line vs. maintenance vs. second-line therapy ) . Tumor response progression assess accord RECIST 1.1 .</brief_summary>
	<brief_title>Erlotinib 100mg qd Versus Gefitinib 250mg qd EGFR Mutant Nsclc</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Diagnosis advance stage NSCLC ( stage IIIB IV ) confirm histology cytology method . 2 . Harboring PCRconfirmed activate mutation EGFR , include exon 19 deletion exon 21 L858R point mutation . 3 . Measurable disease accord RECIST1.1 . 4 . Eastern Cooperative Oncology Group ( ECOG ) score 02 5 . Adequate organ function , define follow : 1 . LVEF &gt; 50 % within institution normal value . 2 . Absolute neutrophil count ( ANC ) &gt; 1500/mm3 . 3 . Platelet count &gt; 75,000/mm3 4 . Estimated creatinine clearance &gt; 45m1/min . 5 . Total bilirubin &lt; 1.5 time institutional ULN ( Patients Gilbert 's Syndrome total bilirubin must &lt; 4 time institutional ULN ) . 6 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &lt; three time institutional upper limit normal ( ULN ) ( relate liver metastasis &lt; five time institutional ULN ) . 6 . Recovered previous therapy relate toxicity ≤CTCAE Grade 1 study entry ( except stable sensory neurupethy ≤CTCAE Grade 2 alopecia ) . 7 . Ability take oral medication opinion investigator . 8 . Age ≥ 18 year . 9 . Written inform consent consistent ICHGCP guideline . 1 . Prior treatment EGFR direct small molecule antibody . 2 . Radiotherapy within 4 week prior randomization , except follow : 1 . Palliative radiation target organ chest may allow 2 week prior randomization 2 . Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol . 3 . Active brain metastasis ( stable &lt; 4 week , symptomatic , leptomeningeal disease ) . Dexamethasone therapy allow administer stable dose least 4 week randomization . 4 . Any current malignancy malignancy diagnose within past three ( 3 ) year ( basalcell carcinoma skin , situ cervical cancer , situ prostate cancer ) . 5 . Known preexist interstitial lung disease . 6 . Significant recent acute gastrointestinal disorder diarrhea major symptom e.g . Crohn 's disease , malabsorption CTC grade &gt; 2 diarrhoea aetiology , base investigator assessment . 7 . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification 3 ( Refer Appendix 10.4 ) , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior randomisation . 8 . Any concomitant serious illness organ system dysfunction opinion investigator would either compromise patient safety interfere evaluation safety test drug . 9 . Women childbearing potential men able father child , unwilling abstinent use adequate contraception prior study entry , duration study participation least 2 month treatment end . Adequate method contraception woman ChildBeanng Potenial discuss Section 4.2.2.3 . 10 . Female patient childbearing potential ( see Section 4.2.2.3 ) nursing pregnant . 11 . Patients unable complv protocol opinion investigator . 12 . Active hepatitis B infection ( detined presence Hepatitis B DNA ) , active hepatitis C infection ( define vresence Hepatitis C RNA ) and/or know HIV carrier . 13 . Known suspected active drug alcohol abuse opinion investigator . 14 . Requirement treatment prohibit concomitant medication list Section 4.2.3 . 15 . Any contraindication therapy gefitinib erlotinib . 16 . Known hypersensitivity erlotinib , gefitinib exipients trial drug 17 . Major surgery within 4 week start study treatment . 18 . Use investigational drug within 4 week randomisation ( unless long time period require local regulation guideline investigational product ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>stage IIIB</keyword>
	<keyword>stage IV )</keyword>
	<keyword>confirm histology cytology method</keyword>
	<keyword>Harboring PCR-confirmed activate mutation EGFR , include exon 19 deletion exon 21 L858R point mutation</keyword>
</DOC>